Mesenchymal Stem Cells Do Not Do What Most People Think

Ask almost anyone what a stem cell injection does and you will get a version of the same picture. The cells go in. They travel to the damaged knee or the injured tendon. They recognize what is broken. They become new cartilage or new tissue in place of what was lost.

It is a clean and satisfying story. It is also, as far as the evidence takes us, mostly wrong.

I want to be precise about what I mean by wrong, because this is not an argument that mesenchymal cells do nothing. It is an argument that the mechanism most patients are carrying around in their heads is not the mechanism researchers now think is doing the work. The real one is, to my mind, quite a bit more interesting. It also matters practically, because what you believe a therapy does determines what you expect from it, how long you wait before deciding it has failed, and which sales pitches you find convincing.

What These Cells Are, and Where They Come From

Mesenchymal cells are most often drawn from bone marrow, from fat tissue, or from birth tissue such as umbilical cord. They can be expanded in culture. They adhere to plastic in a characteristic way, they carry a recognizable set of surface markers, and under deliberately chosen laboratory conditions they can be pushed toward bone, cartilage, and fat lineages. That last property is where the trouble begins, and I will come back to it.

First, the source, because it is treated as a detail and is not one. Marrow, fat, and cord tissue do not yield equivalent cells. They differ in how readily they multiply, in what they secrete, and in how they behave once they are administered. A study showing benefit with cells from one tissue is not evidence for a product made from another.

So when a clinic describes what it offers simply as "stem cells," without naming the tissue of origin, a variable that matters has quietly gone missing. It is the first thing I would ask about, and the answer should be specific.

The Part of the Story That Oversold

In a dish, under conditions selected to make it happen, these cells will differentiate into bone, cartilage, or fat. That is a real and long-reproduced laboratory finding. It is one of the standard criteria the field uses to confirm it is working with the cell type it thinks it is.

The leap was in reading a laboratory capability as a description of what happens inside a person. Injected into a living body, these cells meet an entirely different situation. The evidence that they engraft in meaningful numbers and become durable new tissue at the site of injury is thin. Where researchers have looked carefully, most of the administered cells are cleared within days, and the few that persist are far too few to account for the effects that have been observed.

The name has not helped. The field's own professional body, the International Society for Cell and Gene Therapy, has spent years urging that these be called mesenchymal stromal cells rather than mesenchymal stem cells unless genuine stem-cell behavior has been rigorously demonstrated, on the grounds that the word "stem" promises a kind of tissue replacement the evidence does not support, and that the promise gets used in marketing to patients. When the specialists who study a cell type publicly ask the rest of us to be careful about calling it a stem cell, that is worth pausing on.

What the Evidence Points To Instead

The dominant current understanding is that these cells work mainly by signaling rather than by becoming. The technical word is paracrine, and it means something plain: acting on nearby cells by releasing things.

Administered into injured or inflamed tissue, the cells respond to the environment they land in. They release growth factors, signaling proteins, and small membrane-wrapped packages of cargo, and those signals change the behavior of the cells around them. A large share of the effect appears to be immune modulation: turning down an inflammatory response that has stopped being useful, and shifting the local immune cells toward a repair-oriented posture rather than a destructive one.

Put plainly, these cells behave less like replacement parts and more like a temporary instruction. They arrive, they change the conversation in the neighborhood, and then they are gone. Whether anything lasting comes of it depends largely on whether the tissue was capable of repairing itself given a better environment to do it in.

There is a related point I will only touch on here, because it deserves its own article: where the cells physically end up depends heavily on how they are delivered, and a great many of them never reach the target at all. Route of administration is a real clinical variable rather than a marketing footnote.

Why This Should Change What You Expect

If the mechanism is signaling rather than rebuilding, several things follow, and they are the practical payoff of the whole reframe.

Structure that is gone is unlikely to come back. A therapy that modulates an environment is not a therapy that regrows a joint surface that has been worn away. Symptom improvement without structural change is a legitimate outcome and worth having, but it should be named as what it is rather than described as regeneration.

Effects can be real and still be temporary. If the benefit comes from a signal, it is entirely coherent for that benefit to fade as the signal does. That is not evidence of fraud and it is not evidence of cure. It is what a signaling mechanism looks like.

And the state of the tissue matters enormously. A biological instruction to repair is only useful to tissue that retains the capacity to act on it. This is a large part of why results in this field vary so widely between patients, and why trial results conflict more than anyone would like.

It also gives you a way to weigh what you are told. Claims that the cells will find the damage, become new tissue, and rebuild what was lost are claims the evidence does not currently support. I would treat that language as a signal about the source rather than about the science. The more accurate description, that these cells appear to modulate inflammation and alter the local environment in ways that may support the body's own repair, is less thrilling and is the one I would want to hear.

The Safety Question Is Not Answered at This Level Either

Understanding the mechanism better does not settle whether a given preparation is a good idea for a given person, and I want to be careful not to let one substitute for the other.

Safety here belongs to a specific preparation, from a specific tissue source, processed and dosed in a specific way, delivered by a specific route, in a specific patient. Change any one of those and the answer can change with it. Your medical history matters. What else you are taking matters. An active or recent cancer history deserves a genuinely different conversation when a therapy alters immune signaling and the local growth environment. How you clear things matters. The condition being treated matters most of all, because a reasonable trade against a serious problem can be a poor trade against a minor one.

Two patients can receive vials from the same laboratory, prepared identically, and be in meaningfully different positions. That is not a disclaimer. It is the substance of the question, and it is not one an article can answer for you.

A Word on Who Is Saying This

I work in regenerative medicine and I have commercial interests in the field, which is exactly why I think this correction should come from inside it. The differentiation story sells better than the signaling story. It is more vivid, it justifies a higher price, and it sets an expectation that the treatment will do something permanent.

The incentive to keep telling it is obvious, and it runs in my direction as much as anyone's. It is also worth saying that the opposite reflex, dismissing the entire field as snake oil, tends to come from people with their own positions to protect. The honest reading is that the mechanism is different from the marketing story, and different is not the same as worthless.

The Bottom Line

Mesenchymal cells are not spare parts that travel to an injury and rebuild it. The best current understanding is that they are short-lived signalers that modulate inflammation and change the local environment, and that whatever benefit follows is largely the body's own repair, encouraged. That is a real mechanism worth studying seriously, and it is not the one being sold.

Knowing the difference will not tell you whether any of this is right for you. It will tell you what to expect, what to ask, and when the story you are being told has drifted ahead of the evidence. As ever, this is general education rather than medical advice, and the conversation that actually decides anything is the one with a physician who knows your history.